Karyopharm Therapeutics Inc. financial data

Symbol
KPTI on Nasdaq
Location
85 Wells Avenue, Second Floor, Newton, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 3, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 126 % -61.3%
Quick Ratio 5 % -8.91%
Debt-to-equity -155 % +36.1%
Return On Equity 55.4 % -5.53%
Return On Assets -101 % -145%
Operating Margin -73.1 % +13.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 17.1B shares +13506%
Common Stock, Shares, Outstanding 8.7M shares -93.1%
Entity Public Float 108M USD -46.5%
Common Stock, Value, Issued 13K USD 0%
Weighted Average Number of Shares Outstanding, Basic 8.67K shares +4%
Weighted Average Number of Shares Outstanding, Diluted 8.67K shares +4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 143M USD -3.98%
Research and Development Expense 131M USD -12.1%
Operating Income (Loss) -104M USD +17.3%
Nonoperating Income (Expense) -20.5M USD -153%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -125M USD -42.9%
Income Tax Expense (Benefit) 1K USD -99.7%
Net Income (Loss) Attributable to Parent -125M USD -42.5%
Earnings Per Share, Basic -5 USD/shares +25%
Earnings Per Share, Diluted 0 USD/shares +98.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 37.7M USD -48.3%
Cash, Cash Equivalents, and Short-term Investments 45.9M USD -65.6%
Inventory, Net 3.97M USD -15.1%
Assets, Current 89.7M USD -51.4%
Property, Plant and Equipment, Net 122K USD -75.4%
Operating Lease, Right-of-Use Asset 4.68M USD +81%
Assets 96.2M USD -49.2%
Accounts Payable, Current 5.39M USD -6.76%
Employee-related Liabilities, Current 13.9M USD -15.7%
Accrued Liabilities, Current 66.3M USD +32.4%
Liabilities, Current 87.2M USD +41.7%
Operating Lease, Liability, Noncurrent 6.01M USD
Other Liabilities, Noncurrent 14.1M USD +128%
Liabilities 365M USD +4.69%
Accumulated Other Comprehensive Income (Loss), Net of Tax -259K USD -16.7%
Retained Earnings (Accumulated Deficit) -1.66B USD -8.13%
Stockholders' Equity Attributable to Parent -269M USD -68.7%
Liabilities and Equity 96.2M USD -49.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -39M USD +10.8%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 15.3M USD -30.3%
Common Stock, Shares Authorized 53.3M shares -86.7%
Common Stock, Shares, Issued 8.7M shares -93.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -23.7M USD -8.67%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 38M USD -48%
Interest Paid, Excluding Capitalized Interest, Operating Activities 5.14M USD
Deferred Tax Assets, Valuation Allowance 447M USD +8.45%
Deferred Tax Assets, Gross 1.44M USD +39.5%
Operating Lease, Liability 7.15M USD +17.3%
Depreciation 78K USD -8.24%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -125M USD -43.4%
Lessee, Operating Lease, Liability, to be Paid 10.9M USD +61.6%
Property, Plant and Equipment, Gross 7.09M USD -1.12%
Operating Lease, Liability, Current 922K USD -74.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.88M USD -35.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.49M USD -61%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.73M USD +485%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.93M USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.99M USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 2.8M USD -33%
Interest Expense 27.1M USD +15.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%